Signing a plea agreement that bans hims from the grounds of the University of Virginia and makes him pay court costs, the ...

Heart disease is a type of cardiovascular disease that affects the heart’s structure and function. Several different heart ...

The San Francisco telehealth company had capitalized on the shortage by making copycat versions of popular brand-name GLP-1 ...

I make the case that investors are not paying up for any GLP1 prospects, or even, for that matter, the actual core business that Hims & Hers (NYSE:HIMS) operates in. I argue that there's a lot ...

Hims & Hers Health Q3 2024 revenue projected to surpass estimates by $5M-$10M. Truist consumer survey shows 10% use compounded GLP-1 medications, while 14% prefer branded options. Thursday, The ...

S hares of Hims & Hers (NYSE: HIMS) fell as much as 15% on Thursday after news that Eli Lilly's (NYSE: LLY) GLP-1 drug was taken off the shortage list by the FDA. This could impac ...

Despite semaglutide being the active ingredient in Hims & Hers Health Inc’s (NYSE:HIMS) compounded GLP-1 product, a Truist analyst notes that the recent FDA commentary has reignited investor ...

Hims & Hers Health Inc (HIMS) stock saw a modest uptick, ending the day at $17.66 which represents a slight increase of $0.53 or 3.09% from the prior close of $17.13. The stock opened at $17.55 and ...

Hims & Hers shares tanked after regulators signaled new limits on the production of versions of weight-loss drugs.

Below is Validea's guru fundamental report for HIMS & HERS HEALTH INC (HIMS). Of the 22 guru strategies we follow, HIMS rates highest using our P/B Growth Investor model based on the published ...

Hims & Hers (NYSE:HIMS), the telehealth platform that offers compounded versions of weight loss drugs, dropped more than 10% on Thursday after the FDA confirmed that Eli Lilly's (LLY) GLP-1 ...